Aktie A14SA6 SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Shanghai Haohai Biological Technology Co., Ltd.

Aktien

A14SA6

CNE100001W69

6826

Verzögert Hong Kong S.E.
Andere Börsenplätze
 05:54:13 30.04.2024 		% 5 Tage % 1. Jan.
41,8 HKD +0,60 % Intraday Chart für Shanghai Haohai Biological Technology Co., Ltd. +9,14 % +3,72 %
11.03. Shanghai Haohai's 2023 Gewinn steigt aufgrund höherer Umsätze; Aktien steigen um 5% MT
23.02. Shanghai Haohai Biological Technology Co., Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Shanghai Haohai's 2023 Profit Rises on Higher Revenue; Shares Rise 5%
Shanghai Haohai Biological Technology Co., Ltd. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on July 19, 2024
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Shanghai Haohai Biological Forecasts Up to 138% Boost in 2023 Profit
Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023
Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan announced on September 27, 2023.
Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee
Haohai Biological Technology's Q3 Profit Rises 34%; Hong Kong Shares Jump 5%
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan announced on September 27, 2023.
Shanghai Haohai Biological Technology Co., Ltd. commences an Equity Buyback Plan for 1,538,461 shares, representing 0.9% for CNY 200 million, under the auhtorization approved on September 15, 2023.
Shanghai Haohai Biological Technology to See Rise in January-September Profit
Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023
Shanghai Haohai Biological Technology's Profit Surges 188.9% in H1; Shares Up 3%
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Shanghai Haohai Biological Technology Co., Ltd. authorizes a Buyback Plan.
Shanghai Haohai Biological to Buy Remaining Stake in Medical Aesthetics, Cosmetology Business
Shanghai Haohai Biological Technology Co., Ltd. entered into the equity transfer agreement to acquire 36.3636% stake in OHMK Medical Technology Co., Ltd. from Tianjin Huacan Enterprise Management Consulting Partnership, Shanghai Ermei Enterprise Management Consulting Partnership, Yuan Yibing, Lian Songyong and Chen Guangfei for approximately CNY 150 million.
Shanghai Haohai Biological Technology’s H1 Profit to See Up to 210% Boost
Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14SA6 Aktie
  4. Nachrichten Shanghai Haohai Biological Technology Co., Ltd.
  5. Andere Sprachen